Citius Oncology Stock Market Value
| CTOR Stock | 1.11 0.04 3.48% |
| Symbol | Citius |
Can Life Sciences Tools & Services industry sustain growth momentum? Does Citius have expansion opportunities? Factors like these will boost the valuation of Citius Oncology. Projected growth potential of Citius fundamentally drives upward valuation adjustments. Determining accurate worth demands scrutiny of both present operating results and projected expansion capacity. Evaluating Citius Oncology demands reviewing these metrics collectively while recognizing certain factors exert disproportionate influence.
Investors evaluate Citius Oncology using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Citius Oncology's intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Market participants employ diverse analytical approaches to determine fair value and identify buying opportunities when prices dip below calculated worth. External factors like market trends, sector rotation, and investor psychology can cause Citius Oncology's market price to deviate significantly from intrinsic value.
It's important to distinguish between Citius Oncology's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Citius Oncology should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, Citius Oncology's market price signifies the transaction level at which participants voluntarily complete trades.
Citius Oncology 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Citius Oncology's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Citius Oncology.
| 11/08/2025 |
| 02/06/2026 |
If you would invest 0.00 in Citius Oncology on November 8, 2025 and sell it all today you would earn a total of 0.00 from holding Citius Oncology or generate 0.0% return on investment in Citius Oncology over 90 days. Citius Oncology is related to or competes with Scilex Holding, Actuate Therapeutics, Forte Biosciences, Spero Therapeutics, Vor Biopharma, Seres Therapeutics, and Fate Therapeutics. Citius Oncology is entity of United States More
Citius Oncology Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Citius Oncology's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Citius Oncology upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.08) | |||
| Maximum Drawdown | 40.44 | |||
| Value At Risk | (9.02) | |||
| Potential Upside | 8.73 |
Citius Oncology Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Citius Oncology's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Citius Oncology's standard deviation. In reality, there are many statistical measures that can use Citius Oncology historical prices to predict the future Citius Oncology's volatility.| Risk Adjusted Performance | (0.05) | |||
| Jensen Alpha | (0.53) | |||
| Total Risk Alpha | (0.80) | |||
| Treynor Ratio | (0.57) |
Citius Oncology February 6, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.05) | |||
| Market Risk Adjusted Performance | (0.56) | |||
| Mean Deviation | 4.44 | |||
| Coefficient Of Variation | (1,308) | |||
| Standard Deviation | 6.39 | |||
| Variance | 40.87 | |||
| Information Ratio | (0.08) | |||
| Jensen Alpha | (0.53) | |||
| Total Risk Alpha | (0.80) | |||
| Treynor Ratio | (0.57) | |||
| Maximum Drawdown | 40.44 | |||
| Value At Risk | (9.02) | |||
| Potential Upside | 8.73 | |||
| Skewness | 0.7027 | |||
| Kurtosis | 3.55 |
Citius Oncology Backtested Returns
Citius Oncology secures Sharpe Ratio (or Efficiency) of -0.0321, which signifies that the company had a -0.0321 % return per unit of risk over the last 3 months. Citius Oncology exposes twenty-two different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm Citius Oncology's Standard Deviation of 6.39, risk adjusted performance of (0.05), and Mean Deviation of 4.44 to double-check the risk estimate we provide. The firm shows a Beta (market volatility) of 0.88, which signifies possible diversification benefits within a given portfolio. Citius Oncology returns are very sensitive to returns on the market. As the market goes up or down, Citius Oncology is expected to follow. At this point, Citius Oncology has a negative expected return of -0.21%. Please make sure to confirm Citius Oncology's total risk alpha, kurtosis, as well as the relationship between the Kurtosis and day typical price , to decide if Citius Oncology performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.13 |
Insignificant predictability
Citius Oncology has insignificant predictability. Overlapping area represents the amount of predictability between Citius Oncology time series from 8th of November 2025 to 23rd of December 2025 and 23rd of December 2025 to 6th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Citius Oncology price movement. The serial correlation of 0.13 indicates that less than 13.0% of current Citius Oncology price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.13 | |
| Spearman Rank Test | 0.16 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Pair Trading with Citius Oncology
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Citius Oncology position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Citius Oncology will appreciate offsetting losses from the drop in the long position's value.Moving together with Citius Stock
Moving against Citius Stock
| 0.64 | FTRE | Fortrea Holdings | PairCorr |
| 0.62 | FIBK | First Interstate Ban | PairCorr |
| 0.62 | ENS | Enersys Earnings Call This Week | PairCorr |
| 0.55 | MRVI | Maravai Lifesciences | PairCorr |
| 0.48 | APETF | Alpha Esports Tech | PairCorr |
The ability to find closely correlated positions to Citius Oncology could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Citius Oncology when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Citius Oncology - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Citius Oncology to buy it.
The correlation of Citius Oncology is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Citius Oncology moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Citius Oncology moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Citius Oncology can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Citius Stock Analysis
When running Citius Oncology's price analysis, check to measure Citius Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Citius Oncology is operating at the current time. Most of Citius Oncology's value examination focuses on studying past and present price action to predict the probability of Citius Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Citius Oncology's price. Additionally, you may evaluate how the addition of Citius Oncology to your portfolios can decrease your overall portfolio volatility.